Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/ije/volume-2018/8126087/figures/8126087.fig.003a.svgz" name="8126087.fig.003a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Colorectal NEN</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/ije/volume-2018/8126087/figures/8126087.fig.003b.svgz" name="8126087.fig.003b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Small bowel NEN</td></tr></table>

<div>Plasma Cg A in patients with confirmed progression of colorectal NENs. Baseline levels and concentration of Cg A during follow-up of patients with metastatic colorectal NENs is no different (a) as observed during small bowel neuroendocrine tumor progression (b) [<a href="/journals/ije/2018/8126087/#B65">65</a>].</div>

International Journal of Endocrinology

fig3

Figure 3

Figure 3: Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors 